Evidence map›Paper›PMID 35023206›Full record

ArticleHepatology (Baltimore, Md.)2022

Postvaccination COVID-19 infection is associated with reduced mortality in patients with cirrhosis.

Binu V John, Yangyang Deng, Kaley B Schwartz, Tamar H Taddei, David E Kaplan, Paul Martin, Hann-Hsiang Chao, Bassam Dahman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology (Baltimore, Md.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 3 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Binu V JohnDivision of Hepatology, Miami VA Health System, Miami, Florida, USA.ORCID 0000-0002-2002-9682
Yangyang DengDepartment of Health Behavior and Policy, Virginia Commonwealth University, Richmond, Virginia, USA.
Kaley B SchwartzDivision of Hepatology, Miami VA Health System, Miami, Florida, USA.
Tamar H TaddeiSection of Digestive Diseases, Yale School of Medicine, New Haven, Connecticut, USA.
David E KaplanDivision of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Paul MartinDivision of Hepatology, Miami VA Health System, Miami, Florida, USA.
Hann-Hsiang ChaoDepartment of Radiation Oncology, Central Virginia VA Health Care System, Richmond, Virginia, USA.
Bassam DahmanDepartment of Health Behavior and Policy, Virginia Commonwealth University, Richmond, Virginia, USA.
University of Miami · USVirginia Commonwealth University · USHospital of the University of Pennsylvania · USUniversity of Miami Health System · USVirginia Department of Health · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kim Felder Rhoads · 1985 to 2026
$51.0M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA016059
6 · The paper itself

Abstract

BACKGROUND AND

aimsPatients develop breakthrough COVID-19 infection despite vaccination. The aim of this study was to identify outcomes in patients with cirrhosis who developed postvaccination COVID-19.

methodsWe performed a retrospective cohort study among US veterans with cirrhosis and postvaccination or unvaccinated COVID-19. Patients were considered fully vaccinated if COVID-19 was diagnosed 14 days after the second dose of either the Pfizer BNT162b2, the Moderna 1273-mRNA, or the single-dose Janssen Ad.26.COV2.S vaccines and partially vaccinated if COVID-19 was diagnosed 7 days after the first dose of any vaccine but prior to full vaccination. We investigated the association of postvaccination COVID-19 with mortality.

resultsWe identified 3242 unvaccinated and 254 postvaccination COVID-19 patients with cirrhosis (82 after full and 172 after partial vaccination). In a multivariable analysis of a 1:2 propensity-matched cohort including vaccinated (n = 254) and unvaccinated (n = 508) participants, postvaccination COVID-19 was associated with reduced risk of death (adjusted HR [aHR], 0.21; 95% CI, 0.11-0.42). The reduction was observed after both full (aHR, 0.22; 95% CI, 0.08-0.63) and partial (aHR, 0.19; 95% CI, 0.07-0.54) vaccination, following the 1273-mRNA (aHR, 0.12; 95% CI 0.04-0.37) and BNT162b2 (aHR, 0.27; 95% CI, 0.10-0.71) vaccines and among patients with compensated (aHR, 0.19; 95% CI, 0.08-0.45) and decompensated (aHR, 0.27; 95% CI, 0.08-0.90) cirrhosis. Findings were consistent in a sensitivity analysis restricted to participants who developed COVID-19 after vaccine availability.

conclusionsThough patients with cirrhosis can develop breakthrough COVID-19 after full or partial vaccination, these infections are associated with reduced mortality.

Indexed as

COVID-19BNT162 VaccineBreakthrough InfectionsCOVID-19 VaccinesHumansLiver CirrhosisRetrospective StudiesRNA, MessengerBNT162 VaccineCOVID-19 VaccinesRNA, Messenger

Identifiers

PMID35023206
PMCPMC9015228
OpenAlexW4206710931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.